Heparin and Warfarin in Pregnancy
Samwel Mikaye, CEO of SaMik Medical Center, posted on LinkedIn:
”HEPARIN AND WARFARIN IN PREGNANCY
Anticoagulation may be necessary in pregnancy for conditions like mechanical heart valves, thrombophilia, or previous thromboembolism.
Key principle: Choose an anticoagulant that protects the mother without harming the fetus.
1. HEPARIN
Types
• Unfractionated heparin (UFH)
• Low molecular weight heparin (LMWH) – e.g., Enoxaparin, Dalteparin
Safety
• Does NOT cross the placenta → safe for the fetus
• Preferred anticoagulant in pregnancy, especially in the first trimester
Administration
• UFH: Subcutaneous or IV, frequent monitoring (aPTT)
• LMWH: Subcutaneous, fixed or weight-based dosing, less monitoring needed
Adverse Effects
• Maternal bleeding
• Heparin-induced thrombocytopenia (HIT) – rare with LMWH
• Osteoporosis (with prolonged UFH use)
2. WARFARIN
Safety
• Crosses the placenta → teratogenic
• Avoid in the first trimester due to risk of warfarin embryopathy (nasal hypoplasia, limb defects)
• Risk of fetal bleeding and CNS abnormalities in later trimesters
When Warfarin May Be Used
• In selected high-risk women with mechanical heart valves, after the first trimester, if benefits outweigh risks
• Usually switched to heparin during weeks 6–12, then back to warfarin until near delivery
Monitoring
• Maternal INR target: 2.0–3.0 (varies with valve type)
• Close fetal monitoring recommended
3. MANAGEMENT PRINCIPLES
• First trimester: Prefer LMWH or UFH
• Second trimester: Warfarin may be considered if necessary
• Near term: Switch back to heparin to reduce the risk of fetal bleeding at delivery
• Always coordinate with obstetrics and hematology
KEY POINTS
• Heparin (UFH or LMWH) is safe in all trimesters; does not cross placenta
• Warfarin is teratogenic, especially in the first trimester, and causes fetal bleeding
• Careful switching strategy is required for women with mechanical heart valves
• Close maternal and fetal monitoring is essential”
Stay updated with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis